Bio-Matrix Announces the Completion of Its Medical Device Engineering, Testing and Research Laboratory.SAN DIEGO -- Bio-Matrix Scientific Group, Inc. (Pink Sheets:BMXP BMXP Boston Metropolitan Exchange Point ), a biotechnology company focused on stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. cryogenics cryogenics: see low-temperature physics. cryogenics Study and use of low-temperature phenomena. The cryogenic temperature range is from −238°F (−150°C) to absolute zero. At low temperatures, matter has unusual properties. and disposable stem cell / tissue transfer instruments, (http://www.bmxgonline.com), is pleased to announce the completion of its Medical Device Engineering, Testing and Research Laboratory. The Medical Device Engineering, Testing and Research Laboratory will allow for in-house engineering and testing of medical devices from the development stage all the way through to the refinement stage. The laboratory will not only be used in the development of new medical devices but, it will also serve in the refinement and expansion of the Company's patent pending and proprietary stem cell and tissue transfer instruments. This facility is the first of three specialty research laboratories to be completed. Bio-Matrix' new 15,000 sq ft state-of-the-art facility, located in the heart of San Diego's biotechnology corridor, will house Bio-Matrix' secure Cryogenic Stem Cell Bank, 3 Research laboratories, Aseptic aseptic /asep·tic/ (-tik) free from infection or septic material. a·sep·tic adj. Of, relating to, or characterized by asepsis. Cellular / Tissue Processing Rooms, Hematology, Microbiology and Flow Cytometry flow cytometry (flōˑ sī·t  ˑ·m Laboratories. Brian Pockett, Managing Director and COO, stated, "This timely addition of the research laboratory is direct testament to our hard work and dedication." Mr. Pockett continued to say, "This is a significant milestone for Bio-Matrix as it will allow us to effectively engineer, develop and test out patent pending protected medical devices using state-of-the-art processes and equipment." This press release is available on the company's official online Investor Relations HUB at http://www.agoracom.com/IR/Bio-Matrix for investor questions, answers and monitored commentary. Alternatively, investors are able to e-mail all questions and correspondence to BMXP@agoracom.com where they can also request addition to the investor e-mail list to receive all future press releases and updates in real time. About Bio-Matrix Scientific Group Inc. Bio-Matrix Scientific Group Inc. is a development stage company in the business of medical devices and monitoring systems research, development and commercialization. Bio-Matrix Scientific Group Inc. is aligning itself with partners that offer key technologies in biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. device development, tissue engineering, cell culturing, genome therapy and drug delivery systems. Other companies in the same industry as Bio-Matrix Scientific Group Inc. (Pink Sheets:BMXP) are Cord Blood America (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CBAI CBAI The Community Bankers Association of Illinois CBAI Contract Bridge Association of Ireland (UK) ), StemCells Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :STEM) and Regeneration Technologies (OTCBB:RTIX). More information will be available shortly on the Company's website: www.BMXGonline.com DISCLAIMER: This news release contains forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion